Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms

Oncology Letters

Volumn 14, Issue 2, 2017, Pages 2531-2536

  Zhang, Wenjuan ^a,b,c   Qi, Jiaqian ^a,b,c   Zhao, Shixiang ^a,b,c   Shen, Wenhong ^a,b,c   Dai, Lan ^a,b,c   Han, Wei ^a,b,c   Huang, Man ^a,b,c   Wang, Zhaoyue ^a,b,c   Ruan, Changgeng ^a,b,c   Wu, Depei ^a,b,c   Han, Yue ^a,b,c  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c Key Laboratory of Thrombosis and Haemostasis of the Ministry of Health   (China)

Author keywords

JAK2V617F mutation; Microparticles; Myeloproliferative neoplasms; Splenomegaly; Thrombosis

Indexed keywords

JANUS KINASE 2;

ADULT; ARTICLE; CONTROLLED STUDY; ENDOTHELIAL MICROPARTICLE; FEMALE; FLOW CYTOMETRY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; MIDDLE AGED; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PLATELET MICROPARTICLE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; RED BLOOD CELL MICROPARTICLE; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOSIS; TISSUE FACTOR MICROPARTICLE;

EID: 85021749128     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2017.6459     Document Type: Article

References (32)

1. Tefferi A and Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22: 14-22, 2008.
2. Barrio S, Gallardo M, Arenas A, Ayala R, Rapado I, Rueda D, Jimenez A, Albizua E, Burgaleta C, Gilsanz F and Martinez-Lopez J: Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm. Br J Haematol 161: 667-676, 2013.
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, et al: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397, 2005.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005.
5. Tefferi A: Polycythemi a vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87: 285-293, 2012.
6. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G and Barosi G: Thrombosis in primary myelofibrosis: Incidence and risk factors. Blood 115: 778-782, 2010.
7. Cheung B, Radia D, Pantelidis P, Yadegarfar G and Harrison C: The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia. Br J Haematol 132: 244-245, 2006.
8. Finazzi G, Rambaldi A, Guerini V, Carobbo A and Barbui T: Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92: 135-136, 2007.
9. Willms A, Müller C, Julich H, Klein N, Schwab R, Güsgen C, Richardsen I, Schaaf S, Krawczyk M, Krawczyk M, et al: Tumour-associated circulating microparticles: A novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia. Oncotarget 7: 30867-30875, 2016.
10. Tseng CC, Wang CC, Hsiao CC, Lu HI, Leu S, Chang HC, Huang KT, Fang WF, Chen YM, Liu SF, et al: Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention. Tumour Biol 37: 11873-11882, 2016.
11. Campello E, Zanetto A, Spiezia L, Radu CM, Gavasso S, Ferrarese A, Farinati F, Senzolo M and Simioni P: Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. Thromb Res 143: 118-121, 2016.
12. Owens AP III and Mackman N: Microparticles in hemostasis and thrombosis. Circ Res 108: 1284-1297, 2011.
13. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC and Furie B: Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15: 6830-6840, 2009.
14. Morel O, Luca F, Grunebaum L, Jesel L, Meyer N, Desprez D, Robert S, Dignat-George F, Toti F, Simon C and Goichot B: Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles. Int J Obes (Lond) 35: 1479-1486, 2011.
15. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, et al: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054-1061, 2005.
16. Boulanger CM, Amabile N and Tedgui A: Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension 48: 180-186, 2006.
17. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N and Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: Implications for tumor progression and angiogenesis. Blood 105: 1734-1741, 2005.
18. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH and Francis JL: Tissue factor-bearing microparticles derived from tumor cells: Impact on coagulation activation. J Thromb Haemost 6: 1517-1524, 2008.
19. Thomas GM, Panicot-Dubois L, Lacroix R, Dignat-George F, Lombardo D and Dubois C: Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. J Exp Med 206: 1913-1927, 2009.
20. Weiss HJ: Scott syndrome: A disorder of platelet coagulant activity. Semin Hematol 31: 312-319, 1994.
21. Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, Eichinger S, Kyrle PA and Weltermann A: Tissue factor-positive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97: 119-123, 2007.
22. Garcia Rodriguez P, Eikenboom HC, Tesselaar ME, Huisman MV, Nijkeuter M, Osanto S and Bertina RM: Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. Thromb Res 126: 345-349, 2010.
23. Ma G, Liu F, Lv L, Gao Y and Su Y: Increased promyelocytic-derived microparticles: A novel potential factor for coagulopathy in acute promyelocytic leukemia. Ann Hematol 92: 645-652, 2013.
24. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM and Osanto S: Microparticle-associated tissue factor activity: A link between cancer and thrombosis? J Thromb Haemost 5: 520-527, 2007.
25. Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, Terpstra WE and Falanga A: Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 94: 911-918, 2009.
26. Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B and Abgrall JF: Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res 126: 238-242, 2010.
27. Campello E, Spiezia L, Radu CM, Bulato C, Castelli M, Gavasso S and Simioni P: Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 127: 473-477, 2011.
28. Randhawa J, Ostojic A, Vrhovac R, Atallah E and Verstovsek S: Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol 5: 43, 2012.
29. Lee HS, Park LC, Lee EM, Lee SJ, Shin SH, Im H, Do KM, Kim EJ, Ye BJ, Song MK, et al: Incidence rates and risk factors for vascular events in patients with essential thrombocythemia: A multicenter study from Korea. Clin Lymphoma Myeloma Leuk 12: 70-75, 2012.
30. Lussana F, Caberlon S, Pagani C, Kamphuisen PW, Büller HR and Cattaneo M: Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review. Thromb Res 124: 409-417, 2009.
31. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, Ponziani V, Tozzi L, Pieri L and Santini V: Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 93: 41-48, 2008.
32. Marchetti M, Tartari CJ, Russo L, Panova-Noeva M, Leuzzi A, Rambaldi A, Finazzi G, Woodhams B and Falanga A: Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia. Am J Hematol 89: 68-73,2014.